ClinicalTrials.gg
RecruitingNCT07050823MARES1Updated Jul 25, 2025

Mitigating Chronic Respiratory Disease Through the Lens of Multi-Morbidity

An observational study in Chronic Obstructive Pulmonary Disease (COPD), Asthma and Preserved Ratio Impaired Spirometry, sponsored by University College, London. Recruiting at 2 sites in Brazil. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by University College, London · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
859
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Pulmonary Disease, Chronic Obstructive by University College, London — 4 open to participants now, 4 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · University College, London.

Started
2025
with 3 others
Observational
9 of 14
4 open now
Registered
11th of 14
by date

Among the 14 studies in Pulmonary Disease, Chronic Obstructive by University College, London, this one is one of 4 that started in 2025, is one of 9 observational ones, and was the 11th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

4 of the 14 studies in Pulmonary Disease, Chronic Obstructive by University College, London are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pulmonary Disease, Chronic Obstructive by University College, London, or all of them as a file.
02

Study summary

The investigators aim to make it easier to find people with undiagnosed long-term lung health problems (such as asthma, and chronic obstructive pulmonary disease, COPD, collectively called 'Chronic Respiratory Diseases', CRDs) living in Brasil.

Because people with undiagnosed CRDs often have other medical problems too, such as heart problems, high blood pressure and diabetes (collectively called 'Long Term Conditions', LTC), the investigators will look for undiagnosed CRD in people with LTC when they are attending appointments at local health centres in the cities of Sao Carlos and Sao Paulo.

To look for undiagnosed CRDs the investigators will use two questionnaire-based methods called 'COLA' and 'SBQ'. These are quick and simple to do. All participants will also have tests of their lung function completed including spirometry and Fractional Exhaled Nitric Oxide so that the investigators can make a definite diagnosis of CRDs. When the study is complete, the investigators will examine how well the COLA and SBQ questionnaires perform in identifying people with a definite diagnosis of CRD.

In total, the investigators aim to recruit 859 people.

Read the detailed description

This study aims to evaluate the discriminative capacity of the COLA-6 questionnaire in identifying individuals with chronic respiratory diseases (CRDs) who attend primary health care (PHC) services in Brasil, for the treatment of other long-term conditions (LTCs). To achieve this, the investigators will conduct a cross-sectional observational study enrolling 859 individuals with one or more existing LTCs who are receiving care in PHC services. The COLA-6 questionnaire will be administered, and its results will be compared to gold-standard post-bronchodilator spirometry. The performance of the case-finding tool will be assessed using the area under a receiver operating characteristic (ROC) curve.

This study will be conducted in PHC services, including Basic Health units (BHUs) and Family Health Units (FHUs), located in the municipalities of São Carlos and São Paulo, both situated in the state of São Paulo, Brasil. The municipality of São Carlos has a population of 254,857 inhabitants and a gross domestic product (GDP) of R$55,044.88 per capita, with 34 PHC units. In contrast, São Paulo, the state capital, has a population of 11,451,999 inhabitants and a per capita GDP of R$66,872.84, and is served by 471 PHC units.

Individuals will be recruited from PHC services, including BHUs and FHUs, located in the municipalities of São Carlos and São Paulo, Brasil. Eligible individuals with NCDs will be identified through three main strategies: (1) individuals attending BHUs/FHUs with an established LTC profile (e.g., scheduled consultations or monitoring for hypertension, diabetes, etc.); (2) individuals with LTCs identified by community health agents through proactive outreach; and (3) individuals with LTCs who attend PHC services and become aware of the study through passive recruitment methods such as posters, information shared by staff or other patients, and invitations extended during service days. Additionally, posters containing the research team's contact information will be displayed, and invitations will be extended during service days at the BHUs/FHUs. All recruitment procedures will be conducted in accordance with ethical principles, ensuring the protection of participants' rights to privacy and autonomy.

Data collection will be conducted in a single visit by a member of the UFSCar research team. All eligible participants will provide written Informed Consent prior study procedures. The following procedures will be carried out:

Initial assessment;

Application of case-finding tools questionnaires:

COLA-6 questionnaire; Symptom-Based questionnaire (SBQ); Exhaled fraction of nitric oxide (FeNO) measurement; Spirometry (pre- and post-bronchodilator);

Application of disease-specific questionnaires:

Chronic Airways Assessment Test (CAAT) for all individuals with abnormal spirometry; Asthma Control Questionnaire (ACQ-7) for individuals with isolated or overlapping asthma; provision of basic information on access to downstream healthcare services for diagnosis and treatment of participants identified with abnormal spirometry.

Participants will be classified based on spirometry and FeNO results into two groups, primarily according to the recommendations of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the Global Initiative for Asthma (GINA):

Abnormal Spirometry: Includes COPD, asthma, asthma-COPD overlap, PRISm, restriction patterns, asthma-PRISm overlap and asthma-restriction overlap.

Normal Spirometry: Participants without lung function abnormalities.

The sample size calculation was based on the performance of the COLA-6 questionnaire for diagnosing COPD in the investigators' previous GECo study where COPD prevalence was 9.4%. With these assumed values, a minimum sample size of n=859 individuals will allow the investigators to estimate the area under (AUC) the receiver operating characteristic (ROC) curve to within 4.5% (based on a 95% confidence interval). According to prevalence studies for CRDs in Brasil, the investigators calculate the ability to identify approximately N=146 individuals with COPD, N=77 with asthma, and N=86 with Preserved Ratio Impaired Spirometry (PRISm) in this study, therefore an estimated sample of N=309 with abnormal spirometry and N=550 with normal spirometry. The investigators will case-find in more people if the expected prevalence is lower to reach these targets.

The investigators will summarise the demographic, and clinical characteristics of participants overall and by those with normal and abnormal spirometry. Based on spirometry results, the investigators will report the prevalence of COPD, asthma, PRISm and restriction, alone and in combination, with 95% confidence intervals. For the primary analysis, the investigators will calculate the AUC of the ROC curves for COLA-6 compared with the gold standard spirometry diagnosis separately for combined CRDs, asthma, COPD and PRISm. Using the previously published threshold for COLA-6 scores of ≥4, the investigators will also calculate sensitivity, specificity, and negative and positive predictive values. In addition, based on the ROC curve the investigators will identify the COLA-6 score threshold that achieves sensitivity of at least 90%. All estimates will be reported with 95% confidence intervals.

Full ethical approval was obtained from the Ethics Committee of the Federal University of São Carlos and UNISA (reference number: MARES-1: 85805425.4.1001.5504) and UCL as described above.

The MARES project is funded by the UK NIHR (project reference 303125) using UK international development funding from the UK Government to support global health research. The views expressed in this publication are those of the the investigators and not necessarily those of the NIHR or the UK government.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma
  • Preserved Ratio Impaired Spirometry

Keywords

  • case-finding
  • chronic obstructive pulmonary disease
  • asthma
  • multi-morbidity
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People attending primary care clinics in Brasil for treatment or monitoring of an existing non-respiratory long-term condition, for example cardiovascular disease, diabetes and hypertension.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Attending primary health care services in Brasil.

Diagnosed with one or more existing, non-respiratory long-term conditions such as cardiovascular disease, diabetes or hypertension.

Exclusion criteria

Exclusion Criteria:

Clinically unstable in the past month (defined as worsening symptoms requiring emergency care or hospitalization).

Current pregnancy.

Active pulmonary tuberculosis or undergoing treatment for pulmonary tuberculosis.

Current acute respiratory infection.

Cognitive impairment that prevents understanding of the case-finding questionnaire, defined as score ≤20.

to spirometry.

Declines to participate in the study.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
859 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Discriminative accuracy of the 'COLA' case-finding questionnaire for diagnosis of abnormal spirometry

    The investigators will report the sensitivity, specificity, positive and negative predictive value for the ability of the 'COLA' case-finding questionnaire to identify people with abnormal post-bronchodilator spirometry.

    Time frame: Baseline: all assessments are conducted at one visit and the discriminative accuracy of the 'COLA' case-finding questionnaire for diagnosis of abnormal spirometry will use the COLA and spirometry data from the single visit.

Secondary outcomes

  1. Discriminative accuracy of the 'COLA' case-finding questionnaire for diagnosis of specific patterns of abnormal spirometry

    The investigators will report the sensitivity, specificity, positive and negative predictive value for the ability of the 'COLA' case-finding questionnaire to identify people with asthma, COPD and PRISm separately.

    Time frame: Baseline: all assessments are conducted at one visit and the discriminative accuracy of the 'COLA' case-finding questionnaire for diagnosis of asthma, COPD and PRISm will use the COLA and spirometry data from the single visit.

  2. Discriminative accuracy of the 'SBQ' (symptom based questionnaire) case-finding questionnaire for diagnosis of overall, and specific patterns of abnormal spirometry

    The investigators will report the sensitivity, specificity, positive and negative predictive value for the ability of the 'SBQ' (symptom based questionnaire) case-finding questionnaire to identify people with abnormal spirometry, and asthma, COPD, and PRISm separately.

    Time frame: Baseline: all assessments are conducted at one visit and the discriminative accuracy of the 'SBQ' case-finding questionnaire for diagnosis of abnormal spirometry will use the SBQ and spirometry data from the single visit.

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — On completion of the final report we will consider IPD sharing where this is aligned with the ethics permissions and data governance regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2025
First posted
Jul 3, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jul 2027
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07050823
Collaborators
Universidade Federal de Sao Carlos
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Jul 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jul 25, 2025

Study contacts

Trial Manager
Contact
vivianecastello@ufscar.br
(+5516) 99992-4777
John R Hurst, PhD FRCP
principal investigator · University College London Hospitals
Renata G Mendes, DFisio/ PPGFt
principal investigator · Federal University of Sao Carlos (UFScar), Brasil

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion